FDA Clears Penumbra's Lightning CAVT for Deep Vein Thrombosis, Opening New Market
PEN sits 45% above its 52-week low of $221.26.
Summary
The FDA granted Penumbra's Lightning computer assisted vacuum thrombectomy platform a DVT indication, the first cleared mechanical thrombectomy indication for the condition. The label expansion is backed by the BOLT-DVT IDE trial, which showed 98% complete or near-complete clot removal in a median 18 minutes, a 3.1% 48-hour major adverse event rate, and a 3.9% 30-day re-thrombosis rate. That matters because DVT has been treated with anticoagulation for decades, so a cleared first-line interventional option opens a large adjacent market to Penumbra's existing venous and PE business. The company is already the leading thrombectomy player, and this adds a new growth driver on top of the 20% embolization growth reported in Q2. Note the pending acquisition by Boston Scientific referenced in the forward-looking statements — that deal's timeline remains the dominant variable for the stock.
At the time of this announcement, PEN was trading at $321.73 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.7B. The 52-week trading range was $221.26 to $362.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.